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Abstract
Background: This study aimed to explore Plasmodium falciparum population dynamics during the early phase of
anti-malarial drug treatment with artemisinin-based combination therapy in children with clinical malaria in a high
transmission area in Africa.
Methods: A total of 50 children aged 1-10 years with acute uncomplicated P. falciparum malaria in Bagamoyo
District, Tanzania, were enrolled. Participants were hospitalized and received supervised standard treatment with
artemether-lumefantrine according to body weight in six doses over 3 days. Blood samples were collected 11
times, i.e. at time of diagnosis (-2 h) and 0, 2, 4, 8, 16, 24, 36, 48, 60 and 72 h after initiation of treatment. Parasite
population dynamics were assessed using nested polymerase chain reaction (PCR)-genotyping of merozoite surface
protein (msp) 1 and 2.
Results: PCR-analyses from nine sequential blood samples collected after initiation of treatment identified 20 and
21 additional genotypes in 15/50 (30%) and 14/50 (28%) children with msp1 and msp2, respectively, non-
detectable in the pre-treatment samples (-2 and 0 h combined). Some 15/20 (75%) and 14/21 (67%) of these
genotypes were identified within 24 h, whereas 17/20 (85%) and 19/21 (90%) within 48 h for msp1 and msp2,
respectively. The genotype profile was diverse, and varied considerably over time both within and between
patients, molecular markers and their respective families.
Conclusion: PCR analyses from multiple blood samples collected during the early treatment phase revealed a
complex picture of parasite sub-populations. This underlines the importance of interpreting PCR-outcomes with
caution and suggests that the present use of PCR-adjustment from paired blood samples in anti-malarial drug trials
may overestimate assessment of drug efficacy in high transmission areas in Africa.
The study is registered at http://www.clinicaltrials.gov with identifier NCT00336375.
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Polymerase chain reaction (PCR) adjusted parasitological
cure rate is the recommended primary end-point in clini-
cal trials of anti-malarial drugs conducted in Africa [1].
PCR adjustment is achieved by comparing well character-
ized and highly polymorphic genetic markers of Plasmo-
dium falciparum in a stepwise manner from one blood
sample collected at time of enrolment (pre-treatment
sample) with another blood sample collected at time of
parasite recurrence during follow-up after treatment, i.e.
paired blood samples [2]. The genotypes identified in
these respective single day blood samples are distin-
guished from each other based on size polymorphism.
Detection of the same genotype in both samples indicates
treatment failure (recrudescence), whereas the absence of
any genotype match suggests that the recurrent infection
arose from a new inoculation/infection (treatment suc-
cess)[2]. However, PCR adjusted outcome should be
interpreted with caution due to inherent limitations of
the technique and constraints imposed by the biology of
the parasite [3].
A key issue is whether PCR analysis from paired blood
samples is robust enough to ensure an accurate estimation
of anti-malarial drug efficacy in clinical trials conducted in
high endemic areas in Africa [4,5]. This question has been
raised based on observations that children living in high-
transmission areas often carry complex infections with a
mixture of genetically distinct P. falciparum parasite sub-
populations. Asymptomatic infections are characterized by
extensive dynamics in detection of the individual parasite
genotypes with PCR technique over time, often following a
48 h pattern [6], but sometimes appearing and disappear-
ing within hours [7]. However, the importance and magni-
tude of a similar phenomenon in children with acute
uncomplicated malaria in high-transmission areas remains
incompletely understood. In adult travelers returning from
endemic areas with clinical malaria Färnert et al. reported
a consistent genotype pattern during consecutive day
blood sampling [8], whereas Jafari et al. detected different
genotypes at different time points using a quantitative
method [9]. In Gabonese children treated with intravenous
quinine the same genotype pattern was observed during
the infection, but in some patients alleles disappeared and
reappeared over time [10]. However, the complexity of
infection in this small cohort was relatively low with 7/17
(41%) children harbouring multiclonal infections as
assesses with the msp2 marker only.
Mårtensson et al. have previously reported a study asses-
sing the influence of consecutive daily blood sampling, i.e.
4 consecutive days at enrolment and initiation of treat-
ment and 2 consecutive days at recurrent parasitaemia, on
PCR adjusted cure rates in 106 children with uncompli-
cated P. falciparum malaria in a high-transmission area in
Tanzania [11]. PCR analyses identified at least one addi-
tional genotype in 25% of the patients during 3 days after
enrolment and in 13% on the second day of recurrent
parasitaemia, which were non-detectable at day of enrol-
ment and initial day of recurrent parasitaemia, respec-
tively. This may reflect parasite population dynamics of
P. falciparum or limitations of the PCR-technique to
detect all minority genotypes present due to e.g. template
competition in complex infections [3,11].
Based on these previous findings the present study
was undertaken to explore potential parasite popula-
tion dynamics during the early phase of anti-malarial
drug treatment with artemisinin-based combination
therapy in African children with clinical malaria in
more detail.
Methods
Study site, design and ethics
The study was conducted in June 2006 in Fukayosi Pri-
mary Health Care Centre, Bagamoyo District, Tanzania.
The study site is located in a rural area, where P. falci-
parum is the predominant malaria species and Ano-
pheles gambiae complex the main vector. At the time of
the trial malaria transmission was high, i.e. with an over-
all slide positivity rate of approximately 40%, and peren-
nial with peaks related to the seasonal rainfalls. The
timing of the trial was chosen to coincide with the local
yearly peak in malaria transmission following the main
rainy season in March-May.
By the time of the trial sulphadoxine-pyrimethamine
was the first- and amodiaquine second-line treatment
for uncomplicated malaria in the study area. No artemi-
sinin-containing therapies were available through the
government health care services in the district during
the conduct of the trial.
T h ep r i m a r yo b j e c t i v eo ft h es t u d yw a st oe x p l o r e
parasite population dynamics in children with acute
uncomplicated malaria during 72 h after diagnosis and
initiation of anti-malarial drug treatment. Secondary
objectives included determining parasite clearance
according to microscopy and PCR. The primary end-
point was to compare the total number of P. falciparum
genotypes detected pre-treatment with the accumulated
number of genotypes identified per patient in all blood
samples collected during the trial. The study was con-
sidered as exploratory, which precludes a sample size
calculation. A sample of 50 children was predefined.
The trial was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice. It
was granted ethics clearance by the National Institute
for Medical Research, Dar es Salaam, Tanzania, and the
Regional Ethics Committee, Stockholm, Sweden.
Informed consent was obtained from parents/guardians
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cal Trials [12], with identifier NCT00336375.
Patients and procedures
Patients were recruited among children presenting at
the study site with symptoms and signs compatible with
acute uncomplicated malaria. Inclusion criteria were: a
finger-prick screening blood slide with presence of
P. falciparum asexual parasites with a density of 2,000-
200,000/μL; age 1-10 years; axillary temperature ≥ 37.5°C
or a history of fever in the preceding 24 h; haemoglobin
(Hb) ≥ 70 g/L; informed consent; and a successful inser-
tion of an intra-venous cannula in an ante-brachial vein.
Exclusion criteria were: any cause of fever other than
malaria; symptoms/signs of severe malaria; any danger
signs; any serious underlying disease; intake of anti-
malarial drugs within the last 14 days; known allergy to
artemether-lumefantrine; and daily maximum number of
five enrolments completed due to limited number of
beds available in the study site.
The inclusion criteria used in this trial divert slightly
from the general standards used in efficacy trials of anti-
malarial drugs conducted in Africa, which usually enrol
children <5 years of age with Hb ≥ 50 g/L [13]. However,
the adjustments in inclusion criteria made with regards to
age and Hb in this study were justified by the frequent
blood sampling and the need of insertion of an intra-
venous cannula.
All children excluded during the screening phase were
referred to the clinician in charge of the health facility,
who treated the patients according to standard practice
and national guidelines.
The enrolled patients were hospitalized and randomly
assigned treatment with artemether-lumefantrine (Coar-
tem; Novartis), either accompanied with or without intake
of 200 ml of full cream milk together with each drug dose.
The purpose of the randomization procedure was for a
pharmacokinetic and pharmacodynamic study, which has
been reported elsewhere [13], where all patients partici-
pated in parallel. In the present report all enrolled patients
have been analysed as a single group.
All drug doses were administered by a study nurse
under supervision of the study physician at 0, 8, 24, 36,
48 and 60 h. Children weighing 5-14 kg, 15-24 kg and
25-34 kg were given one, two and three tablets per
dose, respectively, each tablet containing 20 mg arte-
mether and 120 mg lumefantrine. If a child vomited
within 30 min after ingestion of the study drug, the
dose was repeated.
In-patient follow-up duration was 72 h. All clinical data
were recorded in a Case Record Form (CRF). Clinical
assessment and blood sampling were performed in total 11
times for each participant, i.e. at the time of diagnosis (-2
h) and 0, 2, 4, 8, 16, 24, 36, 48, 60 and 72 h post-treatment.
The blood sampling always included both a thick blood
smear for microscopy and collection of circa 100 μLo f
blood on a filter paper (3 MM; Whatman) for genotyping.
The screening blood sample (-2 h) was collected from a
finger-prick (capillary blood). To reduce the discomfort
due to the multiple blood sampling during the trial an
intra-venous cannula was inserted in an ante-brachial vein
just prior to enrolment and initiation of treatment (0 h),
from where the remaining blood samples were to be col-
lected (venous blood). Thus, the two pre-treatment sam-
ples (-2 and 0 h) arose from different sampling routes,
capillary and venous, respectively, whereas the remaining
nine blood samples collected after initiation of treatment
arose from the venous route.
Giemsa-stained thick blood slides were examined
directly in the field by an experienced microscopist by
counting parasites against 200 white blood cells (WBC).
Parasite density was quantified (parasites/μL) by assum-
ing an average of 8,000 leucocytes per μLo fb l o o d .A
negative blood slide was defined as the absence of any
asexual parasite after examining 200 oil-immersion fields.
Quality control was performed for all blood slides cen-
trally (Ifakara Health Research and Development Centre,
Bagamoyo Research and Training Unit) by an indepen-
dent microscopists blinded to the initial blood slide
results.
All blood samples for genotyping were collected on fil-
ter papers, thoroughly dried and put in individual zipper
plastic bags. After completion of the field trial they were
transported to Karolinska Institutet, Sweden, where the
genotyping was performed.
At discharge from the study all participants received
an insecticide treated net free of charge.
Molecular analyses
DNA was extracted from all blood samples collected on
filter paper using the ABI PRISM
® 6100 Nucleic Acid Pre-
pStation (Applied Biosystems, Fresno, CA, USA) as pre-
viously described [14]. Nested PCR genotyping was
performed both for the msp1 and msp2 marker, consid-
ered to be the two most informative genetic markers for
assessment of multiplicity of infection [15,16]. The respec-
tive initial amplification was followed by individual nested
PCR reactions using family specific primers for msp1 (KI,
MAD20 and R033), and msp2 (FC27 and IC), according to
previously described standard protocols [17]. The msp1
and msp2 PCR products were loaded on 3% and 2% agar-
ose gels, respectively, stained with ethidium-bromide,
separated by electrophoresis and visualized under UV
trans-illumination (GelDoc
®, Biorad, Hercules, Ca, USA).
All blood samples collected from the same patient were
processed in parallel during all aspects of the laboratory
work, from DNA extraction to separation of PCR products
on agarose gels. At least 2 positive controls from different
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trol were incorporated in each PCR run.
An adequate PCR outcome was defined for each patient,
as the presence of amplified DNA in at least one genetic
marker in both pre-treatment samples (-2 and 0 h),
together with detectable PCR products in the positive con-
trols. For patients not fulfilling this definition a repeat PCR
run including all blood samples was performed with an
increased DNA template in the initial amplification only, i.
e. 3 μL instead of 1 μL in a total reaction volume of 20 μL.
If an adequate PCR outcome could not be retrieved after
this second PCR attempt, DNA was re-extracted and the
PCR analysis repeated according to the initial protocol.
Analyses of number of genotypes and size polymorph-
ism were digitalized using Quantity One
® software
(Biorad, Hercules, Ca, USA). Individual genotypes were
defined by binning 20 base-pairs intervals together. Initi-
ally, the median genotype for each family of the respective
g e n e t i cm a r k e r sw a si d e n t i f i e d .T h ea b s o l u t es i z eo ft h e
identified median band +/- 10 base-pairs formed the initial
bin. Thereafter, each 20 base pair interval below and
above the median band were defined as representing a dis-
tinct genotype.
Statistical analyses
Data were entered, validated and analysed using SPSS 15.0
software. Arithmetical means were calculated for all con-
tinuous baseline demographic variables, except for asexual
parasite density (geometric mean). Continuous variables
were compared between the two pre-treatment samples as
well as between pre-treatment (-2 and 0 h combined) and
samples collected after treatment initiation using paired
sample t-test. Proportions of binary outcomes for related
samples were compared using McNemar’s c
2 test. Statisti-
cal significance was defined as a P-value ≤0.05. Where
applicable, 95% confidence intervals (CI) were calculated.
The primary end-point was analysed for all patients
enrolled in the study using the intention to treat approach.
To adjust for the differences in methodology for pre-treat-
ment blood sampling, capillary versus venous, the geno-
typing outcome for these two blood samples (-2 and 0 h)
were combined in the analyses of the primary end-point of
the study.
Results
Screening, baseline/pre-treatment characteristics and
compliance
Out of 277 children screened for eligibility, 148 (53%) had
a positive blood-slide for P. falciparum, but 98 (66%) had
to be excluded for the following reasons: parasite density
>200,000/μL (N = 7); parasite density <2,000/μL (N = 25);
age <1 year (N = 5); age >10 years (N = 1); Hb <70 g/L
(N = 11); severe malaria (N = 2); severe malnutrition (N =
1); refused consent (N = 13); recent intake of anti-malarial
drugs (N = 1); not possible to establish an intra-venous
line (N = 11); and maximum daily number of admissions
completed (N = 21).
A total of 50 children were thus enrolled, including 31
(62%) girls and 19 (38%) boys, of whom 33 (66%) were
below 5 years of age. Mean age and weight was 51
(range 12-119) months and 14.3 (range 8.0-30.0) kg,
respectively. Some 37/50 (74%) children were febrile
with a temperature of ≥37.5°C at screening (-2 h). At
this time point 27/50 (54%) children received antipyretic
treatment (paracetamol). A statistically significant
decrease in mean temperature was observed between
the two pre-treatment measurements (-2 and 0 h), from
38.5°C to 37.9°C (p = 0.004; paired sample t-test). In
contrast, parasite geometric mean showed a statistically
significant increase from 21,705 (range 2,120-192,000)
parasites/μL to 37,710 (range 2,120-200,400) parasites/
μL( p = 0.038; paired sample t-test) between -2 and 0 h.
A majority of the patients, 28/50 (56%), had an at least
two-fold difference in parasite density between -2 and
0 h, of whom 21 showed an increase of more than 100%
and 7 a decrease of at least 50%.
No death, development of severe malaria or any other
serious adverse event occurred during the trial. Forty-
nine children completed the stipulated 72-h follow-up.
They all had adequate clinical and parasitological
response by 72 h. The remaining child completed fol-
low-up until 48 h, but was then withdrawn due to guar-
dians’ request. This child had a negative blood slide at
discharge and had received five of the total six arte-
mether-lumefantrine doses under supervision during
study participation. The final drug dose was provided to
the parents to be administered at home.
Parasite positivity rates, PCR success rate and parasite
clearance
From the 50 children enrolled a total of 548 blood samples
were collected for microscopy and genotyping, of which
312 (57%) had a positive blood slide for asexual P. falci-
parum and 365 (67%) a positive PCR amplification in at
least one genetic marker (McNemar’s c
2 test 32.6, p <
0.001). The respective msp1 and msp2 markers were posi-
t i v ei n3 3 0( 6 0 % )a n d3 2 5( 5 9 % )o ft h e5 4 8s a m p l e s .T h e
corresponding PCR positivity rates for the individual
families of msp1 were for KI: 213 (39%) MAD20: 114
(26%) and R033: 152 (28%), and for msp2 FC27: 206 (38%)
and IC: 265 (48%), respectively. A positive PCR result for
at least one genetic marker was also retrieved in 68/236
(29%) blood samples, when microscopy was reported
negative.
The overall PCR success rate, defined as the ability to
amplify parasite DNA in either msp1 or msp2 when micro-
scopy showed asexual P. falciparum parasitaemia, was 297/
312 (95%), and for the individual markers 281/312 (90%)
Carlsson et al. Malaria Journal 2011, 10:380
http://www.malariajournal.com/content/10/1/380
Page 4 of 12and 279/312 (89%) for msp1 and msp2, respectively. An
adequate PCR outcome could be established after the first
PCR attempt in 46/50 (92%) patients. Four patients (ID 5,
8, 11 and 20) required one repeat PCR run, whereafter
they fulfilled the definition of adequate PCR outcome. The
15 samples with overall PCR failure were distributed
among eight patients, of whom four (ID: 5, 8, 11 and 26)
had 2-4 negative samples and the remaining 4 (Patient ID:
15, 34, 39 and 45) had one negative sample each.
Parasite clearance (Figure 1) measured as proportion of
patients with positive microscopy was rapid and effective
following artemether-lumefantrine treatment. By 24 h
after initiation of treatment 27/50 (54% [95% CI 40-68%])
patients had a positive blood slide, whereas 41/50 (82%
[95% CI 71-93%]) remained positive by PCR. From this
time point and onwards PCR clearance was generally
longer as compared with microscopy clearance, leaving
11/50 (22%) and 9/50 (18%) children with a positive PCR
result at 60 and 72 h, respectively, when no samples
remained positive by microscopy.
Genotype diversity and distribution
Total numbers of detectable genotypes and overall base-
pair ranges as well as relative prevalences of the most
detected genotype for the respective families within msp1
and msp2 are presented in Table 1. Overall distribution
and frequencies of individual genotypes during follow-up
is presented in Figure 2.
Complexity of infection and parasite population dynamics
The complexity of infection pre-treatment (-2 and 0 h
combined) was high, with 32/50 (64%) and 37/50 (74%)
patients carrying multiple genotypes in msp1 [median 2,
range 0-7] and msp2 [median 2, range 0-7], respectively. A
total of 16/50 (32%) and 12/50 (24%) patients had different
genotype patterns detected in the two pre-treatment sam-
ples for msp1 and msp2, respectively. This comprised 19
genotypes in msp1 and 18 in msp2. A total of eight msp1
genotypes (6 K1, 1 MAD20 and 1 R033) and eight msp2
(3 FC27 and 5 IC) were detected -2 h but absent 0 h,
whereas 11 (4 K1, 6 MAD20 and 1 R033) and 10 (3 FC27
and 7 IC) genotypes, respectively, appeared at 0 h without
having been identified -2 h.
In the nine sequential blood samples collected after
initiation of treatment, msp1 genotyping identified a total
of 20 (10 KI, 7 MAD20 and 3 R033) genotypes in 15/50
(30%) patients, which were non-detectable pre-treatment
(-2 and 0 h combined). Of these 15 patients, 11 had one, 3
had two and 1 had three new genotypes, respectively.
Similarly, msp2 genotyping after initiation of treatment
Figure 1 P. falciparum clearance measured as proportion of patients with positive blood slides (asexual parasitaemia) and PCR results
(defined as a positive amplification in at least one genetic marker, i.e. msp1 or msp2) at each blood sampling point during the study.
(Error bars represent 95% confidence intervals)
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(28%) children, of whom seven children each had one and
two new genotypes, as compared with the combined pre-
treatment outcome. Including these 20 and 21 new geno-
types as part of the overall complexity of infection the pro-
portion of children harbouring multiple genotypes
increased from 32/50 (64%) and 37/50 (74%) to 36/50
(72%) and 39/50 (78%) for msp1 and msp2, respectively,
without affecting the median number of genotypes
detected in either of the genetic markers.
Figure 3 shows the accumulated proportion of the
initial detection over time of the msp1 and msp2 geno-
types exclusively identified after initiation of treatment.
Of these 20 and 21 genotypes, 15 (75%) and 14 (67%)
Table 1 Basepair range and number of detected genotypes of the respective families of msp1 and msp2
msp1 msp2
K1 MAD20 R033 FC27 IC
Basepair range 141-318 148-265 147-160 198-783 368-768
Basepair interval & prevalence of the most detected genotype among positive PCR samples 239-259
82/284
(29%)
201-221
89/159
(56%)
144-164
152/152
(100%)
316-336
35/226
(15%)
575-595
48/345
(14%)
Number of genotypes 971 1 6 1 6
Total number of genotypes =1 7 =3 2
Figure 2 Overall distribution and frequencies of individual genotypes during follow-up in the entire cohort. Individual genotypes are
represented on the x-axis with the frequency at which they occur (left y-axis) by each blood sampling point during the study (right y-axis)
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(90%) were detected within 48 h for msp1 and msp2,
respectively.
PCR outcome for each participant during the entire
study are presented in Figures 4 (msp1)a n d5( msp2).
The genotype profile fluctuated considerably over time,
both within and between patients, molecular markers
and their respective families making it difficult to cate-
gorize or quantify specific genotype patterns. However,
some general genotype patterns were identified:
a) Continous and fading; one or several genotypes
present pre-treatment, persist/s for some time and
finally fade/disappear.
b) Continuous and fading with appearance of ran-
dom genotypes; this pattern is similar to pattern a
(above), but with additional random band/s appear-
ing at any time-point during follow-up.
c) Intermittent; one or several genotypes present
pre-treatment disappear and reappear over time.
d) Random; no clear pattern can be discerned.
Example of genotype patterns a, b and c (above) is pre-
sented in Figure 6. A majority of patients appeared to have
continues and fading genotype pattern (a). However, geno-
typing results from one patient often revealed a combina-
tion of the above patterns. Patients carrying complex
infections were also likely to have one or few genotypes
detected more frequently than others throughout the
infection, suggesting the presence of dominant genotype/s.
A minority of patients showed extensive genotype
dynamics, e.g. patient ID 2 (Figure 6). This 72 months old
child had a low grade asexual parasitaemia of 2120/μLa t
enrolment, and never a temperature exceeding 37.5°C dur-
ing follow-up.
Discussion
The introduction of PCR genotyping in clinical drug
trials of anti-malarial drugs has significantly improved
the distinction between treatment failure (recrudescence)
and reinfections among recurrent infections post-treat-
ment. The PCR technique is in theory simple and
straight-forward. However, in real life situations the
Figure 3 Accumulated proportion of primary identification during follow-up of msp1 (N = 20, solid line) and msp2 (N = 21, broken
line) genotypes exclusively identified after initiation of treatment
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to amplify minority clones in complex infections, which
is a common feature in children residing in high-trans-
mission areas in Africa, but also due to constraints
imposed by the biology of the parasite, with sequestration
in the deep vascular system during the later part of the
erythrocytic life cycle [3]. However, the accuracy of PCR-
adjusted results in anti-malarial drug trials do not only
rely on the PCR technique per se, but on a chain of differ-
ent events preceding the DNA amplification and separa-
tion of PCR products, from blood sampling in the field
and duration of storage to extraction of parasite DNA,
each being associated with potential risk of influencing
the final PCR outcome and thus the interpretation of the
efficacy of the drugs at test [15,18]. Therefore, PCR
results should be interpreted with caution [3].
Figure 4 Distribution of detectable msp1genotypes over time for each study participant
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with PCR genotyping of msp1 and msp2 during the early
phase of anti-malarial drug treatment in children with
acute uncomplicated P. falciparum infections in a high-
transmission area in Tanzania, were explored in detail.
The results indicate that a single blood sample may not
provide a complete picture of all parasite subpopulations
present in children with acute uncomplicated malaria in
high-transmission areas in Africa. This is in agreement
with our previous observations [11]. However, PCR
Figure 5 Distribution of detectable msp2genotypes over time for each study participant
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early phase of anti-malarial drug treatment in this trial
revealed a more complex picture of parasite sub-popula-
tions, as compared with the daily consecutive blood sam-
ples reported by Mårtenson et al. [11].
Similarly with Mårtensson et al. previous report [11],
a majority of the additional genotypes exclusively
detected after initiation of treatment were identified
within 24 h after enrolment, at a time when 41/50
(82%) children still had a positive PCR amplification in
at least one genetic marker. However, the most pro-
nounced difference in detected genotype pattern was
observed between the two pre-treatment samples (-2
and 0 h). Similarly, a majority of patients had an at least
a twofold difference in parasite density before initiation
of treatment. These observations may reflect a dynamic/
chaotic situation in untreated children with acute
malaria infections, where individual parasite genotypes
increase and decrease in a non-synchronized way in the
peripheral blood and thus within short time periods
may be present in different proportions of the overall
parasitaemia. However, considering that the blood col-
lection from these two sampling points arose from dif-
ferent routes (capillary versus venous), the observations
may also be due to differences in methodology. Interest-
ingly, no data are, to the authors knowledge, available
on comparison of genotyping results from capillary and
venous blood [2].
Figure 6 Example of different PCR patterns. Patient ID 2 is an example of intermittent genotype pattern, whereas ID 29 shows continuous
fading pattern in all markers and ID 48 a continuous fading pattern with random bands in msp2 IC and a random pattern in msp1 MAD20.
*Patient ID 2 is followed by a positive control for msp2 (FC27) and msp1 (R033)
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tern in our trial, presented both with a low grade parasi-
taemia and fever. Despite fulfilling the study inclusion
criteria, this child may have suffered from a self-limiting
cause of fever other than malaria. If so, the genotype
pattern observed may represent an asymptomatic infec-
tion rather than parasite population dynamics in acute
uncomplicated malaria.
It should be underlined that parasite population
dynamics were assessed based on size polymorphisms of
PCR fragments after separation with electrophoresis on
agarose gels. This method still remains one of the
recommended methods in anti-malarial trials to distin-
guish treatment failures (recrudescence) from new infec-
tions [2] and is still widely used in clinical trials.
However, its discriminatory power is generally consid-
ered to be inferior to more recently developed methods,
e.g. capillary electrophoresis [2,19]. This may have influ-
enced the estimation of parasite population dynamics in
this study. Liljander et al. found that individual mea-
surements of the same PCR fragments run in different
lanes on the same agarose gel varied from 2 to 16 base-
pairs [18]. To account for this a conservative approach
was applied when defining individual genotypes by bin-
ning 20 basepairs together.
Conclusions
The results from this study indicate that PCR analyses
from multiple blood samples collected during the early
treatment phase revealed a complex picture of parasite
sub-populations. However, it remains open whether the
complex genotype pattern observed in our study reflects
true parasite population dynamics or limitations of the
PCR-technique to detect all minority genotypes present
due to e.g. template competition in complex infections.
T h er e s u l t su n d e r l i n et h ei m portance of interpreting
PCR outcomes with caution and suggest that the pre-
s e n tu s eo fP C R - a d j u s t m e n tf r o mp a i r e ds i n g l ed a y
blood samples in anti-malarial drug trials may overesti-
mate assessment of drug efficacy in high transmission
areas in Africa.
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